It is Azura’s belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms.
Our additional areas of focus include the development of our novel New Chemical Entities which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action.
Role of Keratolytics in Ophthalmology
Abnormal keratin production, deposition, and aggregation of keratin via disulfide bonds are the central problem in many ophthalmic conditions including Meibomian Gland Dysfunction, Contact Lens Discomfort, and blepharitis. 1, 2, 3
The Association for Research in Vision and Ophthalmology (ARVO) 2023
AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis
AZR-MD-001 restores gland function and improves signs and ocular symptoms of meibomian gland dysfunction (MGD)
AZR-MD-001 efficacy in improving tear film stability and its impact on associated symptoms of meibomian gland dysfunction in a phase 2 trial
Nonclinical assessment of repeat dosing of AZR-MD-001 (selenium sulfide, SeS2, sterile ophthalmic ointment) to the lower eyelid: A novel therapy developed for meibomian gland dysfunction